These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 16772535

  • 21. Inconclusive evidence puts Adderall back on the market.
    Kondro W.
    CMAJ; 2005 Oct 11; 173(8):858. PubMed ID: 16217102
    [No Abstract] [Full Text] [Related]

  • 22. Stimulants for kids with ADHD--how to proceed safely.
    Ken Mehta S, Jacobs I.
    J Fam Pract; 2014 Feb 11; 63(2):E1-5. PubMed ID: 24527478
    [Abstract] [Full Text] [Related]

  • 23. Management of a hyperactive teen and cardiac safety.
    Sowinski H, Karpawich PP.
    Pediatr Clin North Am; 2014 Feb 11; 61(1):81-90. PubMed ID: 24267459
    [Abstract] [Full Text] [Related]

  • 24. Pemoline (Cylert): market withdrawal.
    Hogan V.
    CMAJ; 2000 Jan 11; 162(1):106, 110. PubMed ID: 11216184
    [No Abstract] [Full Text] [Related]

  • 25. Attention deficit hyperactivity disorder in prison.
    Ghanizadeh A, Akhondzadeh S.
    J Am Acad Psychiatry Law; 2009 Jan 11; 37(2):278. PubMed ID: 19535565
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Encouraging news about ADHD drugs and heart risk in adults.
    Harv Ment Health Lett; 2012 Mar 11; 28(9):7. PubMed ID: 22474711
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Drugs for attention deficit-hyperactivity disorder do not increase the mid-term risk of sudden death in children: a meta-analysis of observational studies.
    Mazza M, D'Ascenzo F, Davico C, Biondi-Zoccai G, Frati G, Romagnoli E, Bassi B, Janiri L, Moretti C, Gaita F.
    Int J Cardiol; 2013 Oct 09; 168(4):4320-1. PubMed ID: 23669111
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. [Methylphenidate. A drug for attention deficit disorders to be used with precaution].
    Taéron C.
    Rev Infirm; 2009 Jun 09; (151):47-9. PubMed ID: 19579855
    [No Abstract] [Full Text] [Related]

  • 37. Debate over warnings for ADHD stimulants.
    Child Health Alert; 2006 Apr 09; 24():1. PubMed ID: 16673500
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ, Merkel RL, Moore M, Thorndike F, Muller C, Kovatchev B.
    Pediatrics; 2006 Sep 09; 118(3):e704-10. PubMed ID: 16950962
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.